Mentioned in ?
References in periodicals archive ?
A prospective study of 2-[18F] fluoro-2-deoxy-Dglucose/ positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels.
PET and PET/CT for oncology applications in the abdomen and pelvis: Update and future directions in the age of molecular medicine
Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab
Research and Markets: Handbook of Therapeutic Antibodies: Technologies, Emerging Developments and Approved Therapeutics
25,26) These have included antibodies for imaging colorectal cancer (eg, satumomab pendetide, (27) arcitumomab (24)), prostate cancer (eg, capromab pendetide (28-30)) NHL, (31) liver cancer, (32) myocardial infarcts (imciromab penlefate (33-35)), infection and inflammation (eg, sulesomab, fanolesomab (36-38)), specific infections, (2) and clots, (39) to mention a few that are now available or in development.
Radioactive antibodies: selective targeting and treatment of cancer and other diseases
In 1996, Immunomedics received FDA and European regulatory approval for arcitumomab (CEA-Scan(R)), a diagnostic imaging kit comprised of a small antibody fragment against CEA that targeted a diagnostic isotope to sites of colorectal cancer.
Anti-CEA Monoclonal Antibody Combined With Chemotherapy Demonstrates Positive Preclinical Results in Colon and Breast Cancers; - Findings Presented at 39th Annual Meeting of the American Society of Clinical Oncology -

Medical browser ?
Full browser ?